Skip to main content

Table 2 Vaccine efficacy parameters and assumptions

From: Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

Gender Male Female
HPV genotype 6 11 16 18 6 11 16 18
Against transient infection †,‡
- Cervical, vaginal & vulvar diseases 41.1 62.1 76.0 96.3
- Genital warts & HPV 6, 11 49.0 57.0 76.1 76.1
Against persistent infection
- Anal disease 78.7 96.0 98.8 98.4
- Cervical, vaginal & vulvar diseases 98.8 98.4
- Penile disease 78.7 96.0
Against individual diseases
- Genital warts 84.3 90.9 98.9 100.0
  1. Unit: percentage. Values were derived from [17].
  2. Efficacy against genital infection in males is assumed to prevent transmission of genital infection to females, and vice versa.
  3. Efficacy for 1 and 2 doses assumed to be 23% and 45% of efficacy of the full 3 doses, respectively.
  4. *Efficacy against anal, head and neck, penile cancers is conferred through protection against infection only.